Nakagaki T, Foster D C, Berkner K L, Kisiel W
Department of Pathology, University of New Mexico School of Medicine, Albuquerque 87131.
Biochemistry. 1991 Nov 12;30(45):10819-24. doi: 10.1021/bi00109a001.
Previous studies demonstrated proteolytic activation of human blood coagulation factor VII by an unidentified protease following complex formation with tissue factor expressed on the surface of a human bladder carcinoma cell line (J82). In the present study, an active-site mutant human factor VII cDNA (Ser344----Ala) has been constructed, subcloned, and expressed in baby hamster kidney cells. Mutant factor VII was purified to homogeneity in a single step from serum-free culture supernatants by immunoaffinity column chromatography. Mutant factor VII was fully carboxylated, possessed no apparent clotting activity, and was indistinguishable from plasma factor VII by SDS-PAGE. Cell binding studies indicated that mutant factor VII bound to J82 tissue factor with essentially the same affinity as plasma factor VII and was cleaved by factor Xa at the same rate as plasma factor VII. In contrast to radiolabeled single-chain plasma factor VII that was progressively converted to two-chain factor VIIa on J82 monolayers, mutant factor VII was not cleaved following complex formation with J82 tissue factor. Incubation of radiolabeled mutant factor VII with J82 cells in the presence of recombinant factor VIIa resulted in the time-dependent and tissue factor dependent conversion of single-chain mutant factor VII to two-chain mutant factor VIIa. Plasma levels of antithrombin III had no discernible effect on the factor VIIa catalyzed activation of factor VII on J82 cell-surface tissue factor but completely blocked this reaction catalyzed by factor Xa. These results are consistent with an autocatalytic mechanism of factor VII activation following complex formation with cell-surface tissue factor, which may play an important role in the initiation of extrinsic coagulation in normal hemostasis.
先前的研究表明,人凝血因子VII与人类膀胱癌细胞系(J82)表面表达的组织因子形成复合物后,会被一种未知的蛋白酶进行蛋白水解激活。在本研究中,构建了一个活性位点突变的人因子VII cDNA(Ser344→Ala),进行亚克隆并在幼仓鼠肾细胞中表达。通过免疫亲和柱层析从无血清培养上清液中一步纯化得到均一的突变型因子VII。突变型因子VII完全羧化,无明显凝血活性,通过SDS-PAGE与血浆因子VII无法区分。细胞结合研究表明,突变型因子VII与J82组织因子的结合亲和力与血浆因子VII基本相同,并且被因子Xa切割的速率与血浆因子VII相同。与在J82单层细胞上逐渐转化为双链因子VIIa的放射性标记单链血浆因子VII不同,突变型因子VII与J82组织因子形成复合物后未被切割。在重组因子VIIa存在的情况下,将放射性标记的突变型因子VII与J82细胞孵育,导致单链突变型因子VII随时间和组织因子依赖性地转化为双链突变型因子VIIa。血浆抗凝血酶III水平对因子VIIa催化的J82细胞表面组织因子上因子VII的激活没有明显影响,但完全阻断了因子Xa催化的该反应。这些结果与因子VII与细胞表面组织因子形成复合物后激活的自催化机制一致,这可能在正常止血过程中外源性凝血的启动中起重要作用。